BACKGROUND: Treatment of aggressive pituitary adenomas typically involves a multimodality approach based on histopathological features and may include pharmacotherapy, surgery, and occasionally radiation therapy. In cases of treatment-refractory tumor progression, chemotherapy may be considered; however, no standard chemotherapeutic regimen has been established. Literature review suggests that temozolomide may have a beneficial role in a subset of cases. To understand the efficacy of temozolomide in progressive pituitary tumors, we reviewed the outcomes of cases at our center. METHODS: We performed a retrospective chart review to report the outcome and unique features of 7 patients with aggressive functioning pituitary adenomas or carcinomas treated with temozolomide. Tumor pathology included somatotroph (n = 1), corticotroph (n = 3), and lactotroph (n = 3) tumors. RESULTS: Four of the 7 patients had at least 2 prior resections, and all had prior radiation and surgery before treatment with temozolomide. Notably, all patients showed response to therapy, defined as either stable disease (43%) or partial response (57%). Median progression-free survival was 1.66 years, and median overall survival was 4 years. CONCLUSION: Our data suggest that temozolomide has an important role in the management of aggressive functioning pituitary tumors that are resistant to standard therapies, and that optimization of therapy with temozolomide may involve individualized regimens. Future prospective clinical trials should be considered.
BACKGROUND: Treatment of aggressive pituitary adenomas typically involves a multimodality approach based on histopathological features and may include pharmacotherapy, surgery, and occasionally radiation therapy. In cases of treatment-refractory tumor progression, chemotherapy may be considered; however, no standard chemotherapeutic regimen has been established. Literature review suggests that temozolomide may have a beneficial role in a subset of cases. To understand the efficacy of temozolomide in progressive pituitary tumors, we reviewed the outcomes of cases at our center. METHODS: We performed a retrospective chart review to report the outcome and unique features of 7 patients with aggressive functioning pituitary adenomas or carcinomas treated with temozolomide. Tumor pathology included somatotroph (n = 1), corticotroph (n = 3), and lactotroph (n = 3) tumors. RESULTS: Four of the 7 patients had at least 2 prior resections, and all had prior radiation and surgery before treatment with temozolomide. Notably, all patients showed response to therapy, defined as either stable disease (43%) or partial response (57%). Median progression-free survival was 1.66 years, and median overall survival was 4 years. CONCLUSION: Our data suggest that temozolomide has an important role in the management of aggressive functioning pituitary tumors that are resistant to standard therapies, and that optimization of therapy with temozolomide may involve individualized regimens. Future prospective clinical trials should be considered.
Authors: Luis V Syro; Humberto Uribe; Luis C Penagos; Leon D Ortiz; Camilo E Fadul; Eva Horvath; Kalman Kovacs Journal: Clin Endocrinol (Oxf) Date: 2006-10 Impact factor: 3.478
Authors: V J Moyes; G Alusi; H I Sabin; J Evanson; D M Berney; K Kovacs; J P Monson; P N Plowman; W M Drake Journal: Eur J Endocrinol Date: 2008-11-04 Impact factor: 6.664
Authors: Kalman Kovacs; Bernd W Scheithauer; Matilde Lombardero; Roger E McLendon; Luis V Syro; Humberto Uribe; Leon D Ortiz; Luis C Penagos Journal: Acta Neuropathol Date: 2007-10-10 Impact factor: 17.088
Authors: Camilo E Fadul; Andrew L Kominsky; Louise P Meyer; Linda S Kingman; William B Kinlaw; C Harker Rhodes; Clifford J Eskey; Nathan E Simmons Journal: J Neurosurg Date: 2006-10 Impact factor: 5.115
Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Lisa M Neff; Michelle Weil; Alan Cole; Thomas R Hedges; William Shucart; Donald Lawrence; Jay-Jiguang Zhu; Arthur S Tischler; Ronald M Lechan Journal: Pituitary Date: 2007 Impact factor: 4.107
Authors: Shereen Ezzat; Sylvia L Asa; William T Couldwell; Charles E Barr; William E Dodge; Mary Lee Vance; Ian E McCutcheon Journal: Cancer Date: 2004-08-01 Impact factor: 6.860
Authors: Giuseppe Minniti; Sergio Paolini; Marie Lise Jaffrain Rea; Andrea Isidori; Claudia Scaringi; Ivana Russo; Mattia Falchetto Osti; Luigi Cavallo; Vincenzo Esposito Journal: J Neurooncol Date: 2020-07-06 Impact factor: 4.130